Amylx Pharmaceuticals Inc vs Teucrium Soybean Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $23.99 (market cap $2.64B), while Teucrium Soybean Fund trades at $24.82. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Teucrium Soybean Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | SOYB | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $24.19 | $26.28 |
52-Week Low | $7.82 | $21.46 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →